Effects of simvastatin intensive lipid-lowering therapy on serum hs-CRP,TNF-α, IL-6, MMP -9, MMP -2 in patients with acute myocardial infarction
10.3969/j.issn.1005-1678.2017.04.105
- VernacularTitle:辛伐他汀强化降脂治疗对急性心肌梗死患者血清hs-CRP、TNF-α、IL-6、MMP-9、MMP-2的影响
- Author:
Huifei ZHOU
;
Jing ZOU
- Keywords:
acute myocardial infarction;
MMP-9;
MMP-2;
inflammatory factor
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):317-319
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of serum MMP-9,MMP-2 and inflammatory factor levels by intensive lipid-lowering therapy in patients with acute myocardial infarction.Methods A total of 76 cases with acute myocardial infarction from May 2012 to October 2016 in our hospital were collected and randomly divided into control group and experiment group with 38 cases in each group.Patients in the control group were treated by clinical routine lipid-lowering(simvastatin 20mg/day); patients in the experiment group were treated by clinical intensive lipid-lowering(simvastatin 80mg/day),treated for two weeks.Observed the serum MMP-9,MMP-2 and inflammatory factor levels changed of the two groups before and after treatment,explored the validity and security of intensive lipid-lowering therapy in the treatment of patients with acute myocardial infarction.Results After treatment,the clinical efficacy of the experiment group was better than control group,performanced as: the serum MMP-9 and MMP-2 levels of the experiment group were more lower than the control group; the serum hs-CRP,TNF-αand IL-6 levels significant lower than the control group,the above results had statistical significance(P<0.05).The adverse reactions of the experiment group were slight,back to normal after stopped drugs.Conclusion Intensive lipid-lowering therapy in the treatment of patients with acute myocardial infarction can significantly reduce serum MMP-9 MMP-2 and inflammatory factor levels,and high safety.
